The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA)

W. U. Kim, S. Y. Min, M. L. Cho, J. Youn, J. K. Min, S. H. Lee, S. H. Park, C. S. Cho, H. Y. Kim

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The aim of this study was to investigate the role of IL-12 in patients with RA. IL-12 (p70) and its associated cytokines were measured in sera and synovial fluid (SF) using an enzyme-linked immunosorbent method. Seven American College of Rheumatology (ACR) core set measures as well as IL-12 levels were sequentially monitored at the commencement and 4 months after treatment with a low-dose steroid and disease-modifying anti-rheumatic drugs (DMARDs). In sera, 64 (42.2%) of 152 RA patients had detectable concentrations of IL-12 (p70), whereas one (1.4%) of 69 osteoarthritis (OA) patients and five (10%) of 50 healthy controls had detectable IL- 12 (P<0.001). The median level of circulating IL-12 was also higher in RA patients (P< 0.001). In SF, the number of patients with detectable IL-12 and the median IL-12 levels were significantly higher in RA patients (n = 53) than in OA patients (n = 22). In paired samples (n = 53) of sera and SF from RA patients, IL-12 levels were higher in the SF than in sera (P<0.001). Patients with detectable IL-12 (n = 51) in sera had higher tender joint scores (P = 0.003), swollen joint scores (P<0.001) and C-reactive protein (CRP; P = 0.036), than those without (n = 55). Four months after treatment with DMARDs, the improved group showed a larger IL-12 decrease than the non- improved group (P = 0.017). The levels of IL-12 correlated positively with those of IL-2, interferon-gamma, IL-6, and tumour necrosis factor-alpha, but were correlated inversely with those of IL-10. Our results demonstrate that IL-12 levels reflect RA disease activity and that IL-12 is involved in the production of proinflammatory cytokines. An IL-12 blockade could be useful for the treatment of RA.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalClinical and Experimental Immunology
Volume119
Issue number1
DOIs
StatePublished - 2000

Fingerprint

Interleukin-12
Rheumatoid Arthritis
Synovial Fluid
Serum
Antirheumatic Agents
Osteoarthritis
Joints
Cytokines
Immunosorbents
Interleukin-10
C-Reactive Protein
Interferon-gamma
Interleukin-2
Interleukin-6
Therapeutics

Keywords

  • Disease activity
  • IL-12
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology

Cite this

The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). / Kim, W. U.; Min, S. Y.; Cho, M. L.; Youn, J.; Min, J. K.; Lee, S. H.; Park, S. H.; Cho, C. S.; Kim, H. Y.

In: Clinical and Experimental Immunology, Vol. 119, No. 1, 2000, p. 175-181.

Research output: Contribution to journalArticle

Kim, W. U. ; Min, S. Y. ; Cho, M. L. ; Youn, J. ; Min, J. K. ; Lee, S. H. ; Park, S. H. ; Cho, C. S. ; Kim, H. Y. / The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). In: Clinical and Experimental Immunology. 2000 ; Vol. 119, No. 1. pp. 175-181.
@article{4d8c29fe3b484bbebe9600c81671660b,
title = "The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA)",
abstract = "The aim of this study was to investigate the role of IL-12 in patients with RA. IL-12 (p70) and its associated cytokines were measured in sera and synovial fluid (SF) using an enzyme-linked immunosorbent method. Seven American College of Rheumatology (ACR) core set measures as well as IL-12 levels were sequentially monitored at the commencement and 4 months after treatment with a low-dose steroid and disease-modifying anti-rheumatic drugs (DMARDs). In sera, 64 (42.2{\%}) of 152 RA patients had detectable concentrations of IL-12 (p70), whereas one (1.4{\%}) of 69 osteoarthritis (OA) patients and five (10{\%}) of 50 healthy controls had detectable IL- 12 (P<0.001). The median level of circulating IL-12 was also higher in RA patients (P< 0.001). In SF, the number of patients with detectable IL-12 and the median IL-12 levels were significantly higher in RA patients (n = 53) than in OA patients (n = 22). In paired samples (n = 53) of sera and SF from RA patients, IL-12 levels were higher in the SF than in sera (P<0.001). Patients with detectable IL-12 (n = 51) in sera had higher tender joint scores (P = 0.003), swollen joint scores (P<0.001) and C-reactive protein (CRP; P = 0.036), than those without (n = 55). Four months after treatment with DMARDs, the improved group showed a larger IL-12 decrease than the non- improved group (P = 0.017). The levels of IL-12 correlated positively with those of IL-2, interferon-gamma, IL-6, and tumour necrosis factor-alpha, but were correlated inversely with those of IL-10. Our results demonstrate that IL-12 levels reflect RA disease activity and that IL-12 is involved in the production of proinflammatory cytokines. An IL-12 blockade could be useful for the treatment of RA.",
keywords = "Disease activity, IL-12, Rheumatoid arthritis",
author = "Kim, {W. U.} and Min, {S. Y.} and Cho, {M. L.} and J. Youn and Min, {J. K.} and Lee, {S. H.} and Park, {S. H.} and Cho, {C. S.} and Kim, {H. Y.}",
year = "2000",
doi = "10.1046/j.1365-2249.2000.01095.x",
language = "English (US)",
volume = "119",
pages = "175--181",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA)

AU - Kim, W. U.

AU - Min, S. Y.

AU - Cho, M. L.

AU - Youn, J.

AU - Min, J. K.

AU - Lee, S. H.

AU - Park, S. H.

AU - Cho, C. S.

AU - Kim, H. Y.

PY - 2000

Y1 - 2000

N2 - The aim of this study was to investigate the role of IL-12 in patients with RA. IL-12 (p70) and its associated cytokines were measured in sera and synovial fluid (SF) using an enzyme-linked immunosorbent method. Seven American College of Rheumatology (ACR) core set measures as well as IL-12 levels were sequentially monitored at the commencement and 4 months after treatment with a low-dose steroid and disease-modifying anti-rheumatic drugs (DMARDs). In sera, 64 (42.2%) of 152 RA patients had detectable concentrations of IL-12 (p70), whereas one (1.4%) of 69 osteoarthritis (OA) patients and five (10%) of 50 healthy controls had detectable IL- 12 (P<0.001). The median level of circulating IL-12 was also higher in RA patients (P< 0.001). In SF, the number of patients with detectable IL-12 and the median IL-12 levels were significantly higher in RA patients (n = 53) than in OA patients (n = 22). In paired samples (n = 53) of sera and SF from RA patients, IL-12 levels were higher in the SF than in sera (P<0.001). Patients with detectable IL-12 (n = 51) in sera had higher tender joint scores (P = 0.003), swollen joint scores (P<0.001) and C-reactive protein (CRP; P = 0.036), than those without (n = 55). Four months after treatment with DMARDs, the improved group showed a larger IL-12 decrease than the non- improved group (P = 0.017). The levels of IL-12 correlated positively with those of IL-2, interferon-gamma, IL-6, and tumour necrosis factor-alpha, but were correlated inversely with those of IL-10. Our results demonstrate that IL-12 levels reflect RA disease activity and that IL-12 is involved in the production of proinflammatory cytokines. An IL-12 blockade could be useful for the treatment of RA.

AB - The aim of this study was to investigate the role of IL-12 in patients with RA. IL-12 (p70) and its associated cytokines were measured in sera and synovial fluid (SF) using an enzyme-linked immunosorbent method. Seven American College of Rheumatology (ACR) core set measures as well as IL-12 levels were sequentially monitored at the commencement and 4 months after treatment with a low-dose steroid and disease-modifying anti-rheumatic drugs (DMARDs). In sera, 64 (42.2%) of 152 RA patients had detectable concentrations of IL-12 (p70), whereas one (1.4%) of 69 osteoarthritis (OA) patients and five (10%) of 50 healthy controls had detectable IL- 12 (P<0.001). The median level of circulating IL-12 was also higher in RA patients (P< 0.001). In SF, the number of patients with detectable IL-12 and the median IL-12 levels were significantly higher in RA patients (n = 53) than in OA patients (n = 22). In paired samples (n = 53) of sera and SF from RA patients, IL-12 levels were higher in the SF than in sera (P<0.001). Patients with detectable IL-12 (n = 51) in sera had higher tender joint scores (P = 0.003), swollen joint scores (P<0.001) and C-reactive protein (CRP; P = 0.036), than those without (n = 55). Four months after treatment with DMARDs, the improved group showed a larger IL-12 decrease than the non- improved group (P = 0.017). The levels of IL-12 correlated positively with those of IL-2, interferon-gamma, IL-6, and tumour necrosis factor-alpha, but were correlated inversely with those of IL-10. Our results demonstrate that IL-12 levels reflect RA disease activity and that IL-12 is involved in the production of proinflammatory cytokines. An IL-12 blockade could be useful for the treatment of RA.

KW - Disease activity

KW - IL-12

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0033979006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033979006&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2249.2000.01095.x

DO - 10.1046/j.1365-2249.2000.01095.x

M3 - Article

VL - 119

SP - 175

EP - 181

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -